tiprankstipranks
Advertisement
Advertisement

CH:BSLN Stock Latest News

Basilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs
Company AnnouncementsBasilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs
1h ago
BARDA injects $30 million into Basilea’s phase 3 antifungal program
PremiumCompany Announcements
BARDA injects $30 million into Basilea’s phase 3 antifungal program
7d ago
PremiumCompany Announcements
Basilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs
2M ago
PremiumCompany Announcements
Basilea Wins CARB-X Funding Boost for First-in-Human Trial of Novel Antibiotic BAL2420
4M ago
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
PremiumCompany Announcements
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
5M ago
Basilea Pharmaceutica Earnings Call Highlights Pipeline Push
PremiumCompany AnnouncementsBasilea Pharmaceutica Earnings Call Highlights Pipeline Push
6M ago
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
Premium
Company Announcements
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
6M ago
Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
Premium
Company Announcements
Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
8M ago
BSLN
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
PremiumRatings
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
8M ago
Basilea Achieves Sales Milestone with Cresemba in Europe
PremiumCompany Announcements
Basilea Achieves Sales Milestone with Cresemba in Europe
9M ago
Basilea Secures BARDA Funding for Novel Antibiotic Development
PremiumCompany Announcements
Basilea Secures BARDA Funding for Novel Antibiotic Development
10M ago
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
PremiumRatings
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
11M ago
Basilea Secures Additional BARDA Funding for Antifungal Development
PremiumCompany AnnouncementsBasilea Secures Additional BARDA Funding for Antifungal Development
11M ago
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
Premium
Company Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
11M ago
BSLN
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
Premium
Company Announcements
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
11M ago
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
11M ago
BSLN
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
PremiumCompany Announcements
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
12M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
12M ago
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
PremiumCompany Announcements
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
12M ago
PremiumCompany AnnouncementsBasilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
12M ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
12M ago
Premium
Company Announcements
Basilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors
12M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >